Health Canada grants IVD approval to Devyser’s NGS-based chimerism test, the first of its kind in Canada
Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been...
In this case study, Dr. Papasavva describes her laboratory’s journey from traditional thalassemia testing to state-of-the-art NGS technology and what a difference this has made in their daily work.
Whitepaper
This whitepaper explores the diagnostic
challenges posed by the α3.7 and α4.2 deletions in
alpha thalassemia testing and the opportunities to
overcome the limitations of traditional methods.
In this whitepaper, you will learn:
• The molecular basis and clinical implications of the
α3.7 and α4.2 deletions.
• Key challenges in the detection of these deletions
using traditional diagnostic methods.
• Advances in NGS technologies and their impact on
thalassemia diagnostics.
• The need for integrated data analysis software to
enable accessibility to thalassemia genetic testing.
Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been...
Read More
Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its...
Read More
Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical...
Read More
Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its...
Read More